Business
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH)
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 –","length":225,"tagName":"p"},{"type":"text","content":"– Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica’s candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical –","length":320,"tagName":"p"},{"type":"text","content":"– Conference call scheduled for today at 4:30 pm ET –","length":53,"tagName":"p"},{"type":"text","content":"WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced financial results for the quarter ended March 31, 2025.","length":301,"tagName":"p"},{"type":"text","content":"“I am pleased to report that our focused commercialization strategy is helping to drive increased demand for YCANTH and the demand has allowed us to normalize distributor inventory levels. For the first time, we dispensed more than 10,000 applicator units in a quarter. We are excited by the strong pull-through from our distributors, which translated to $3.4 million in revenue in the first quarter, and we expect this closer alignment between dispensed applicator units and revenue to continue going forward. Furthermore, we saw momentum in dispensed applicator units build throughout the first quarter and we are looking to build on that momentum in the second quarter,” said Dr. Jayson Rieger, Ph...